[Form 4] Pulse Biosciences, Inc Insider Trading Activity

Rhea-AI Filing Summary

Pulse Biosciences director Manmeet Singh was granted a stock option covering 30,000 shares of common stock with an exercise price of $16.16. The option was issued on 08/15/2025, is exercisable through 08/15/2035 and covers 30,000 underlying shares.

The option will vest in equal monthly installments over a one-year period, contingent on the reporting person’s continued service, with the first vesting installment occurring on September 15, 2025. The reporting person holds the option directly.

Positive

• Option grant is clearly defined with exercise price, term, and vesting schedule disclosed
• Vesting occurs over one year in equal monthly installments, providing a short, clear alignment of service to equity vesting

Negative

• Potential dilution is explicit: the option covers 30,000 underlying shares upon exercise
• No contextual metrics provided (total outstanding shares or prior holdings) to assess materiality or dilution impact

Insights

Corporate Governance Expert

TL;DR: A routine director equity grant with short vesting schedule; governance impact appears limited and retention-focused.

The filing discloses a direct grant of a 10-year option for 30,000 shares at $16.16 to a company director. The one-year monthly vesting schedule is relatively short, aligning near-term incentives with continued service. There is no indication in the form of accelerated vesting, performance conditions, or related-party transactions beyond the director relationship. Given only the disclosed grant, this appears to be a standard equity compensation event rather than a governance change.

Compensation Analyst

TL;DR: Compensation-wise this is a straightforward stock-option award; size and strike are explicit but company-level impact is not provided.

The option’s terms are clearly stated: 30,000 options, $16.16 strike, exercisable until 08/15/2035, vesting monthly over one year starting September 15, 2025. The grant vests fully within a year, which may accelerate potential equity realization compared with multi-year schedules. The reported information does not include prior holdings, total outstanding shares, or grant rationale, limiting assessment of dilution or cost to shareholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Soni Manmeet Singh

(Last) (First) (Middle)

601 BRICKELL KEY DRIVE

SUITE 1080

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16.16	08/15/2025		A		30,000		(1)	08/15/2035	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 15, 2025.

	/s/ Kenneth B. Stratton, as Attorney-in-Fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pulse Biosciences (PLSE) report on this Form 4?

The company reported a stock option grant to director Manmeet Singh covering 30,000 shares with a $16.16 exercise price.

When does the option vest and when can it be exercised for PLSE?

The option vests in equal monthly installments over one year with the first installment on September 15, 2025, and is exercisable through 08/15/2035.

How many shares are underlying the derivative security reported for PLSE?

30,000 shares of common stock are the underlying amount disclosed in the filing.

What is the exercise price of the options reported for PLSE?

$16.16 per share is the stated conversion/exercise price in the Form 4.

Is the option held directly or indirectly by the reporting person?

The filing states the ownership form is Direct (D) for the reported option.